AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a first-line treatment for breast cancer after camizestrant hit the mark in a ...

Tris Pharma has set its sights on an FDA filing for pipeline drug cebranopadol before the end of this year after the drug achieved significant pain relief in abdominoplasty patients in a late-stage ...